Trials / Unknown
UnknownNCT04833205
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hui Bu · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimotuzumab | Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks |
Timeline
- Start date
- 2021-04-19
- Primary completion
- 2022-04-19
- Completion
- 2023-04-19
- First posted
- 2021-04-06
- Last updated
- 2021-04-20
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04833205. Inclusion in this directory is not an endorsement.